It was found that administering antibodies that target IL-17, its receptor IL-17RA, and IL-5 can disrupt this axis and significantly decrease the number of Th17 cells and eosinophils, hence preventing the progression of multiple myeloma and indicating a promising therapeutic approach (Figure 2) [39]. Here, IL17A is linked to plasma cell myeloma.